Last reviewed: May 31, 2026 Last updated: May 31, 2026 Written by: Jay Hastings , CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
43 FerranniniE.Pereira-MoreiraR.SeghieriM.RebelosE.SouzaA
Travel and schedule adjustments Travel is the most common real-world reason people need to adjust tirzepatide timing
Research from the STEP trial program shows that 1.0 mg is where the dose-response curve starts to steepen meaningfully
Post-transcriptional and post-translational regulation of central carbon metabolic enzymes in cancer
To test whether the effects of GLP-1(2836) require its ability to interact with MTP, we knocked down MTP expression using a siRNA and repeated our Seahorse experiments